Wall Street brokerages expect Ra Pharmaceuticals Inc (NASDAQ:RARX) to post ($0.47) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Ra Pharmaceuticals’ earnings, with estimates ranging from ($0.48) to ($0.45). Ra Pharmaceuticals reported earnings per share of ($0.49) in the same quarter last year, which suggests a positive year-over-year growth rate of 4.1%. The company is scheduled to issue its next earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Ra Pharmaceuticals will report full year earnings of ($1.93) per share for the current financial year, with EPS estimates ranging from ($2.02) to ($1.87). For the next year, analysts anticipate that the firm will post earnings of ($2.39) per share, with EPS estimates ranging from ($2.87) to ($1.90). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Ra Pharmaceuticals.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.02.

RARX has been the topic of several analyst reports. Raymond James set a $49.00 price objective on Ra Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, April 10th. Zacks Investment Research downgraded Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, March 14th. Stifel Nicolaus assumed coverage on Ra Pharmaceuticals in a report on Friday, February 8th. They issued a “buy” rating and a $55.00 price target for the company. BMO Capital Markets set a $33.00 price target on Ra Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 8th. Finally, ValuEngine upgraded Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $36.03.

Large investors have recently bought and sold shares of the stock. Group One Trading L.P. acquired a new position in Ra Pharmaceuticals during the first quarter valued at $34,000. Quantamental Technologies LLC purchased a new position in Ra Pharmaceuticals in the fourth quarter valued at about $44,000. Legal & General Group Plc grew its stake in Ra Pharmaceuticals by 57.7% in the fourth quarter. Legal & General Group Plc now owns 3,063 shares of the company’s stock valued at $56,000 after purchasing an additional 1,121 shares in the last quarter. Great West Life Assurance Co. Can purchased a new position in Ra Pharmaceuticals in the fourth quarter valued at about $63,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Ra Pharmaceuticals by 163.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,014 shares of the company’s stock valued at $68,000 after purchasing an additional 1,868 shares in the last quarter. 90.73% of the stock is currently owned by hedge funds and other institutional investors.

RARX stock traded up $0.40 during midday trading on Wednesday, hitting $23.71. 167,026 shares of the company’s stock were exchanged, compared to its average volume of 435,105. The company has a quick ratio of 20.10, a current ratio of 20.10 and a debt-to-equity ratio of 0.02. Ra Pharmaceuticals has a 12-month low of $5.86 and a 12-month high of $27.68. The company has a market capitalization of $957.32 million, a PE ratio of -11.51 and a beta of 0.79.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

See Also: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.